Published in TB and Outbreaks Week, May 17th, 1999
Rifampin is a first-line drug useful in the treatment of tuberculosis. By using biocompatible polymeric excipients of lactide and glycolide copolymers, two microsphere formulations were developed for targeted and sustained delivery of rifampin, with minimal dosing.
A small-microsphere formulation, with demonstrated ability to inhibit intracellularly replicating Mycobacterium tuberculosis H37Rv, was tested along with a large-microsphere formulation in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week